Business Wire

Eaton’s Vehicle Group Secures U.S. Department of Energy Grant to Develop Emissions-reducing Technologies for the Agricultural Sector

16.12.2021 21:15:00 EET | Business Wire | Press release

Share

Power management company Eaton today announced its Vehicle Group has secured a $2.4 million grant from the U.S. Department of Energy (DOE) to develop new technologies to reduce emissions from agricultural equipment. This grant will accelerate Eaton’s progress in achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005939/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s variable valve actuation technologies are an ideal solution for reducing emissions produced by agricultural implements. (Photo: Business Wire)

Under the grant, Eaton plans to develop technologies that simultaneously reduce greenhouse gas (GHG) by 10% and nitrogen oxides (NOx) by 90% for agricultural powertrains designed for multiple-duty cycles. The technologies are required to span application diversity in the segment while being both cost-efficient and robust. Separately, Eaton also received a $4.9 million grant to develop a new compact and modular solid-state transformer to reduce the cost and size of DC fast-charging systems.

“Off-highway sector emissions levels, including in the agricultural segment, significantly lag behind on-road applications due to a lack of technology solutions,” said Dr. Mihai Dorobantu, director, Technology Planning and Government Affairs, Eaton’s Vehicle Group. “This grant could enable significant reductions in both GHG and NOx emissions that would then drive the technology and its benefits nationwide and help us meet our corporate sustainability objectives. The DOE funding supports our ongoing work to develop technologies that reduce emissions in applications that are difficult to decarbonize. The funding also enables research partnerships to optimize architectures and components.”

To achieve the grant’s objective, Eaton’s Vehicle Group will develop new components for agricultural applications and will modify existing technologies developed for commercial vehicles, including engine and aftertreatment systems. Agricultural solutions differ from advanced on-road technologies because they are used in unique and varying operating cycles.

An expansive portfolio of technologies will be leveraged to achieve target goals

By partnering with leading engine manufacturers, Eaton plans to achieve the DOE targets through innovative technologies that provide higher engine compression ratios, reduce friction and increase turbo machinery efficiency while minimizing mechanical losses.

Eaton will adapt its line of variable-valve actuation (VVA) solutions, originally designed for commercial vehicles, for agricultural use. Eaton’s VVA technologies are based on two building blocks — a rocker with a switchable capsule, and a split rocker for full deactivation. By combining these two building blocks, several VVA strategies can be utilized in virtually any engine architecture — from single and dual overhead cam to cam-in-designs, for engine displacements ranging from 2.0 to 15.0 liters.

Cylinder deactivation (CDA) is a VVA technology that consists of deactivating the intake and exhaust valve opening, as well as the fuel injection on some of the cylinders when the engine is running at low load. CDA is an ideal solution for commercial vehicles that make frequent stops, as well as many agricultural implements. CDA can reduce NOx emissions by up to 40% and carbon dioxide (CO2) by 5%-8%.

Eaton will also focus on active catalyst heating technology to assist with exhaust thermal management as part of achieving the DOE’s targets. Active heating solutions provide heat directly to the vehicle’s aftertreatment system, reducing harmful NOx emissions by warming the selective catalytic reduction (SCR) catalyst to approximately 200-250 degrees Celsius as quickly as possible, and maintaining this temperature during periods of low-load operation.

Additionally, Eaton plans to leverage its positive-displacement TVS® exhaust gas recirculation (EGR) pump to meet the program’s objectives. The EGR pump complements a high-efficiency turbocharger to reduce engine pumping losses, thereby increasing fuel economy and lowering emissions. Because the pump is a positive-displacement device, the engine controller uses the pump speed signal, as well as other Controller Area Network (CAN) sensor data, to accurately calculate EGR mass flow rate.

“This program is foundational to creating two market drivers in the off-highway segment —upcoming regulations to lower GHG and NOx emissions across the segment, and a significant economic benefit generated for end users,” Dorobantu said.

The DOE DC fast-charging grant aims to significantly reduce the time it takes to install charging infrastructures at end-user facilities. Eaton’s new technology will feature advanced components and an innovative cooling approach, eliminating the need for multiple power conversion devices. The goal is to reduce charging infrastructure barriers to commercial electric vehicle deployment by minimizing the need for facility modifications and allowing for charging installations in remote areas. The grant aligns with the DOE’s commitment to have zero-emission vehicles make up half of all vehicles sold in America by 2030 and achieve net-zero emissions economywide by 2050.

The grant also supports Eaton’s Vehicle Group and eMobility business's mission to produce sustainable solutions that enhance vehicle efficiency, safety and performance. Our Vehicle products include emission control components, engine valves, valvetrain systems, superchargers, transmissions, clutches and torque management systems. Our eMobility portfolio includes intelligent power electronics, reliable power distribution and protection solutions, and efficient power systems for electrified vehicles.

Learn more about Eaton’s Vehicle Group and eMobility businesses.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye